Publications

August 6, 2026

Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial

Nat Med 32, 3268-3275 (2026)

AUTHORS:

Yang Zhang, Xiaohan Chi, Rui Feng, Na Xian, Na Huang, Shenjun Sun, Xiaobin Zhao, Peng Zhang, Kang Liu, Yiwen Ma, Yu Zhang, Kangna Zhang, Sihui Wang, Xianzhen Chen, Jindong Zhang, Wuqing Huang, Baozhu Huang, Tina Tinajiao Su, Jacky Yeung, Jianwei He, Lieoing Chen, Nan Ji & Gangxiong Huang

Read More

January 25, 2022

Ablation of T cell-associated PD-1H enhances functionality and promotes adoptive immunotherapy

AUTHORS: Li Hu, Ling Chen, Zexiu Xiao, Xu Zheng, Yuangui Chen, Na Xian, Christina Cho, Liqun Luo, Gangxiong Huang, Lieping Chen
Read More

March 11, 2020

Promoting NK cell trafficking to improve therapeutic effect of NK cell therapy on osteosarcoma

AUTHORS: Yuanzheng Yang, Nancy Gordon, Eugenie S Kleinerman, Gangxiong Huang
Read More

November 4, 2019

B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models

AUTHORS: Baozhu Huang, Liqun Luo, Jun Wang, Bailin He, Rui Feng, Na Xian, Qiong Zhang, Lieping Chen, Gangxiong Huang
Read More

November 1, 2018

Repeat Infusion of CD19-Specific Chimeric Antigen Receptor T-Cell Could Improve the Efficacy with Consistent Safety in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

AUTHORS: Jianda Hu, Ting Yang, Xiaozhu Yang, Na Xian, Yanxin Chen, Peifang Jiang, Gangxiong Huang
Read More

January 1, 2012

Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases

AUTHORS: Gangxiong Huang, Ling Yu, Laurence Jn Cooper, Mario Hollomon, Helen Huls, Eugenie S Kleinerman
Read More

March 2, 2001

B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production

AUTHORS: Andrei I. Chapoval, Jian Ni, Julie S. Lau, Ryan A.Wilcox, Dallas B. Flies, Ding Liu, Haidong Dong, Gabriel L. Sica, Gefeng Zhu, Koji Tamada, Lieping Chen
Read More

June 3, 1997

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

AUTHORS: Ignacio Melero, Walter W. Shuford, Stephanie Ashe Newby, Alejandro Aruffo, Jeffrey A. Ledbetter, Karl Erik Hellström, Robert S. Mittler, Lieping Chen
Read More

Gangxiong Huang, MD

Co-founder, CEO

Dr. Huang’s research has focused on tumor metastasis and T-cell immunotherapy. He completed his postdoctoral training and subsequently served as a researcher at The University of Texas MD Anderson Cancer Center. He also served as a pathologist and Minjiang Scholar Professor at Fujian Medical University previously.

Lieping Chen, MD, PhD​

Co-founder, Scientific advisor

Dr. Chen is a pioneer in cancer immunotherapy. His research focuses on fundamental T-cell biology and the translation of scientific discoveries into clinical therapies, with a primary emphasis on cancer immunotherapy. He discovered PD-L1 and established its role in tumor immune evasion, laying the foundation for anti-PD-1/PD-L1 therapies that have transformed cancer treatment worldwide. Among his other numerous discoveries, B7-H3 has emerged as a promising universal therapeutic target for solid tumors. 

Dr. Chen is United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine at Yale University. He held faculty positions at the Mayo Clinic, Johns Hopkins University, and scientist positions in the Bristol-Myers Squibb Co. before joining Yale University. Dr. Chen is a member of the National Academy of Sciences, the National Academy of Medicine, and a Fellow of the American Association for Cancer Research.